Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  AVEO Pharmaceuticals, Inc.    AVEO

Delayed Quote. Delayed  - 10/21 09:59:34 pm
0.7314 USD   -1.16%
10/17 AVEO PHARMACEUT : AVEO) Files An 8-K
10/12 AVEO PHARMACEUT : to Present at the 15th Annual BIO Investor Forum
09/30 AVEO ONCOLOGY : Announces Proposed Settlement and Settlement Hearing..
News SummaryMost relevantAll newsSector news 

AVEO Pharmaceuticals, Inc. : DEADLINE ALERT: Rigrodsky & Long, P.A. Reminds Shareholders of AVEO Pharmaceuticals, Inc. of Upcoming Deadline

share with twitter share with LinkedIn share with facebook
share via e-mail
06/25/2013 | 11:25pm CEST

Rigrodsky & Long, P.A.:

  • Do you, or did you, own shares of AVEO Pharmaceuticals, Inc. (NASDAQ GS: AVEO)?
  • Did you purchase your shares before January 3, 2012, or between January 3, 2012 and May 1, 2013, inclusive?
  • Did you lose money in your investment in AVEO Pharmaceuticals, Inc.?
  • Do you want to discuss your rights?

Rigrodsky & Long, P.A., including former Special Assistant United States Attorney, Timothy J. MacFall, reminds shareholders of AVEO Pharmaceuticals, Inc. ("AVEO" or the "Company") (NASDAQ GS: AVEO) of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company.

A complaint was filed in the United States District Court for the District of Massachusetts on behalf of all persons or entities that purchased the common stock of AVEO between January 3, 2012 and May 1, 2013, inclusive (the "Class Period"), alleging violations of the Securities Exchange Act of 1934 against the Company and certain of its officers (the "Complaint"). If you wish to serve as lead plaintiff, you must move the Court no later than July 8, 2013.

If you purchased shares of AVEO during the Class Period, or purchased shares prior to the Class Period and still hold AVEO, and wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact Timothy J. MacFall, Esquire or Peter Allocco of Rigrodsky & Long, P.A., 825 East Gate Boulevard, Suite 300, Garden City, NY at (888) 969-4242, by e-mail to info@rigrodskylong.com, or at: http://www.rigrodskylong.com/investigations/aveo-pharmaceuticals-inc-aveo.

A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. In order to be appointed lead plaintiff, the Court must determine that the class member's claim is typical of the claims of other class members, and that the class member will adequately represent the class. Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. Any member of the proposed class may move the court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.

While Rigrodsky & Long, P.A. did not file the Complaint in this matter, the firm, with offices in Wilmington, Delaware and Garden City, New York, regularly litigates securities class, derivative and direct actions, shareholder rights litigation and corporate governance litigation, including claims for breach of fiduciary duty and proxy violations in the Delaware Court of Chancery and in state and federal courts throughout the United States.

Attorney advertising. Prior results do not guarantee a similar outcome.

Rigrodsky & Long, P.A.
Timothy J. MacFall, Esquire
Peter Allocco
Fax: 302-654-7530

© Business Wire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
10/14 AVEO PHARMACEUTICALS INC : Notice of Delisting or Failure to Satisfy a Continued..
10/13 AVEO PHARMACEUTICALS : Oncology Announces Proposed Settlement and Settlement Hea..
10/12 AVEO PHARMACEUTICALS : to Present at the 15th Annual BIO Investor Forum
09/30 AVEO PHARMACEUTICALS INC : Other Events, Financial Statements and Exhibits (form..
09/30 AVEO ONCOLOGY : Announces Proposed Settlement and Settlement Hearing in 2014 Sto..
09/12 AVEO PHARMACEUTICALS INC : Other Events (form 8-K)
09/06 AVEO PHARMACEUTICALS : to Present at the 18th Annual Rodman & Renshaw Global Inv..
08/15 AVEO PHARMACEUTICALS : Initiates the Evaluation of Tivozanib in Combination with..
08/04 AVEO PHARMACEUTICALS : reports 2Q loss
More news
Sector news : Bio Therapeutic Drugs
10/21DJU.S. HOT STOCKS : Hot Stocks to Watch
10/20DJALKERMES : Shares Surge
10/20 ACTELION : raises guidance for third time this year on strong PAH sales
10/18 Pfizer to start shipping biosimilar version of J&J's Remicade in November
10/17DJPfizer Plans to Launch Remicade Biosimilar in November
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
08/15 AVEO initiates early-stage study of tivozanib and Opdivo in kidney cancer
08/04 AVEO Pharmaceuticals beats by $0.01, beats on revenue
05/26 AVEO's late-stage study of lead product candidate tivozanib in difficult-to-t..
05/18 BIOTECH FORUM DAILY DIGEST : Will Anacor Kick Off M&A Wave? Spotlight On 'Lotter..
05/13 AVEO secures private $17M capital raise
Financials ($)
Sales 2016 1,60 M
EBIT 2016 -31,0 M
Net income 2016 -34,8 M
Debt 2016 -
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017
Capi. / Sales 2016 34,6x
Capi. / Sales 2017 6,67x
Capitalization 55,5 M
More Financials
Duration : Period :
AVEO Pharmaceuticals, Inc. Technical Analysis Chart | AVEO | US0535881090 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Mean consensus BUY
Number of Analysts 2
Average target price 2,38 $
Spread / Average Target 225%
Consensus details
EPS Revisions
More Estimates Revisions
Michael P. Bailey President, Chief Executive Officer & Director
Keith S. Ehrlich Chief Financial Officer
Michael N. Needle Chief Medical Officer
Emile Farhan Vice President-Technical Operations
Anthony B. Evnin Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
AMGEN, INC.-2.35%118 623
GILEAD SCIENCES, INC.-26.58%98 037
More Results